Rome, 27 January 2020 - Takis and Evvivax, two biotechnology companies present in the science park of Castel Romano, Rome announce their commitment for the development of innovative vaccines against 2019-nCoV, the new coronavirus originating in Wuhan, China. To date, the virus has caused 81 deaths and over 2,800 known infections and is rapidly expanding in various countries.

The authorization comes from the Ministry of Health and represents the first step in bringing the vaccine to human use. Takis researchers are the only ones in Italy and the first in Europe to access this phase of the experimentation.